RS60725B1 - Fuzioni proteini fgf21 sa dugotrajnim dejstvom i farmaceutska kompozicija koja obuhvata iste - Google Patents

Fuzioni proteini fgf21 sa dugotrajnim dejstvom i farmaceutska kompozicija koja obuhvata iste

Info

Publication number
RS60725B1
RS60725B1 RS20201024A RSP20201024A RS60725B1 RS 60725 B1 RS60725 B1 RS 60725B1 RS 20201024 A RS20201024 A RS 20201024A RS P20201024 A RSP20201024 A RS P20201024A RS 60725 B1 RS60725 B1 RS 60725B1
Authority
RS
Serbia
Prior art keywords
long
pharmaceutical composition
same
fusion proteins
fgf21 fusion
Prior art date
Application number
RS20201024A
Other languages
English (en)
Inventor
Jun Hwan Kim
Seyoung Lim
Minji Seo
Hyun Ho Choi
Dohoon Kim
Mi Kyeong Ju
Ju-Young Park
Byung Hyun Choi
Jun Kyung Lee
Jong Gyun Kim
Su Youn Nam
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of RS60725B1 publication Critical patent/RS60725B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
RS20201024A 2015-10-28 2016-10-28 Fuzioni proteini fgf21 sa dugotrajnim dejstvom i farmaceutska kompozicija koja obuhvata iste RS60725B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020150150574A KR20170049319A (ko) 2015-10-28 2015-10-28 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
PCT/KR2016/012288 WO2017074117A1 (en) 2015-10-28 2016-10-28 Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same
EP16860300.9A EP3368554B1 (en) 2015-10-28 2016-10-28 Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same

Publications (1)

Publication Number Publication Date
RS60725B1 true RS60725B1 (sr) 2020-09-30

Family

ID=58630685

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20201024A RS60725B1 (sr) 2015-10-28 2016-10-28 Fuzioni proteini fgf21 sa dugotrajnim dejstvom i farmaceutska kompozicija koja obuhvata iste

Country Status (22)

Country Link
US (2) US11142557B2 (sr)
EP (2) EP3368554B1 (sr)
JP (2) JP7303629B2 (sr)
KR (1) KR20170049319A (sr)
CN (1) CN108290937B (sr)
AU (2) AU2016346864B2 (sr)
BR (1) BR112018008676A2 (sr)
CA (1) CA3003109A1 (sr)
CY (1) CY1123307T1 (sr)
DK (1) DK3368554T3 (sr)
ES (1) ES2815540T3 (sr)
HK (1) HK1257375A1 (sr)
HR (1) HRP20201392T1 (sr)
HU (1) HUE051036T2 (sr)
LT (1) LT3368554T (sr)
MX (1) MX2018005194A (sr)
PT (1) PT3368554T (sr)
RS (1) RS60725B1 (sr)
RU (1) RU2741087C2 (sr)
SI (1) SI3368554T1 (sr)
WO (1) WO2017074117A1 (sr)
ZA (1) ZA201802002B (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170049320A (ko) * 2015-10-28 2017-05-10 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR20170049319A (ko) 2015-10-28 2017-05-10 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US11179440B2 (en) 2016-11-10 2021-11-23 Yuhan Corporation Pharmaceutical composition containing FGF21 mutant fusion protein and method for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis
EP3612637A4 (en) 2017-04-21 2021-01-27 Yuhan Corporation DOUBLE-FUNCTION PROTEIN PRODUCTION PROCESS AND ITS DERIVATIVES
US11642395B2 (en) * 2017-09-08 2023-05-09 Bristol-Myers Squibb Company Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH)
JP2021528422A (ja) * 2018-06-21 2021-10-21 サノフイＳａｎｏｆｉ 最適化された活性比を有するｆｇｆ２１化合物／ｇｌｐ−１ｒアゴニストの組合せ
CN108635571B (zh) * 2018-07-19 2021-10-22 西安交通大学医学院第一附属医院 鸢尾素(irisin)在制备预防及治疗重症急性胰腺炎药物中的应用
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CA3123325A1 (en) * 2019-03-05 2020-09-10 Sunshine Lake Pharma Co., Ltd. A polypeptide molecule and application thereof
JP2022530216A (ja) * 2019-04-23 2022-06-28 エルジー・ケム・リミテッド 免疫グロブリンのＦｃ領域およびＧＤＦ１５を含む融合ポリペプチド
WO2021152396A1 (en) * 2020-01-31 2021-08-05 89Bio Ltd. Methods for promoting weight loss
CN115109137A (zh) * 2021-03-19 2022-09-27 广东东阳光药业有限公司 Fgf21多肽及其融合多肽的应用
CN113198002A (zh) * 2021-05-12 2021-08-03 上海交通大学医学院附属第九人民医院 一种用于治疗非酒精性脂肪肝的肝细胞因子bmp9
TW202317645A (zh) * 2021-07-05 2023-05-01 大陸商上海翰森生物醫藥科技有限公司 一種融合蛋白及其醫藥用途
CN113717269B (zh) * 2021-08-31 2022-04-19 赣江中药创新中心 一种重组的变体fgf21蛋白及其制备方法和应用
WO2023245543A1 (en) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Uses of fgf21 fusion proteins

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
WO1990002175A1 (en) 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
SI1641823T1 (sl) 2003-06-12 2011-12-30 Lilly Co Eli Fuzijski proteini analogni glp-1
EP1735340A2 (en) * 2004-03-17 2006-12-27 Eli Lilly And Company Glycol linked fgf-21 compounds
US9441030B2 (en) 2007-02-23 2016-09-13 Sk Chemicals Co., Ltd. Process for producing and purifying factor VIII and its derivatives
EP2162472B1 (en) * 2007-05-30 2013-02-27 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
JP2010535781A (ja) 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
SG195542A1 (en) * 2008-10-10 2013-12-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
CN116925238A (zh) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
AU2010246038A1 (en) * 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
CN107188950B (zh) * 2009-05-05 2021-09-28 安姆根有限公司 Fgf21突变体及其用途
EP2440235A1 (en) 2009-06-11 2012-04-18 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
EP2526117B1 (en) * 2010-01-22 2015-05-06 Novo Nordisk A/S Process for preparing fgf-21 with low degree of o-glycosylation
CN103124562A (zh) * 2010-06-08 2013-05-29 诺沃—诺迪斯克有限公司 Fgf21的类似物和衍生物
EP2595647A1 (en) 2010-07-20 2013-05-29 Novo Nordisk A/S N-terminal modified fgf21 compounds
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
EP2661445A2 (en) * 2011-01-04 2013-11-13 Universität Zürich Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
CA2845357A1 (en) * 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
CN102558358A (zh) 2011-12-30 2012-07-11 张海涛 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
US9475856B2 (en) * 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
US9550820B2 (en) * 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
US10286078B2 (en) * 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
LT3412302T (lt) 2014-10-24 2021-07-26 Bristol-Myers Squibb Company Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
KR20170049319A (ko) 2015-10-28 2017-05-10 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR20170049320A (ko) * 2015-10-28 2017-05-10 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
CN105288592A (zh) 2015-11-02 2016-02-03 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21成熟肽在制备肝纤维化治疗药物中的应用
US11179440B2 (en) * 2016-11-10 2021-11-23 Yuhan Corporation Pharmaceutical composition containing FGF21 mutant fusion protein and method for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis
US20220127322A1 (en) 2017-03-14 2022-04-28 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
EP3612637A4 (en) 2017-04-21 2021-01-27 Yuhan Corporation DOUBLE-FUNCTION PROTEIN PRODUCTION PROCESS AND ITS DERIVATIVES

Also Published As

Publication number Publication date
JP7453943B2 (ja) 2024-03-21
CN108290937B (zh) 2022-03-08
BR112018008676A2 (pt) 2018-11-27
HRP20201392T1 (hr) 2020-11-27
RU2741087C2 (ru) 2021-01-22
KR20170049319A (ko) 2017-05-10
AU2016346864B2 (en) 2021-03-18
MX2018005194A (es) 2018-07-06
HK1257375A1 (zh) 2019-10-18
JP2018534929A (ja) 2018-11-29
AU2021204115A1 (en) 2021-07-15
EP3368554A4 (en) 2019-06-19
PT3368554T (pt) 2020-09-10
EP3368554A1 (en) 2018-09-05
LT3368554T (lt) 2020-09-25
DK3368554T3 (da) 2020-08-31
HUE051036T2 (hu) 2021-01-28
EP3368554B1 (en) 2020-08-05
CA3003109A1 (en) 2017-05-04
ZA201802002B (en) 2019-05-29
US11142557B2 (en) 2021-10-12
CY1123307T1 (el) 2021-12-31
CN108290937A (zh) 2018-07-17
JP7303629B2 (ja) 2023-07-05
RU2018119141A (ru) 2019-12-02
JP2021184727A (ja) 2021-12-09
ES2815540T3 (es) 2021-03-30
RU2018119141A3 (sr) 2020-03-24
US20220002367A1 (en) 2022-01-06
AU2016346864A1 (en) 2018-05-10
SI3368554T1 (sl) 2020-10-30
US20180305428A1 (en) 2018-10-25
EP3744731A1 (en) 2020-12-02
WO2017074117A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
HK1257375A1 (zh) 長效fgf21融合蛋白及包含其的藥物組合物
HK1257373A1 (zh) 雙功能蛋白質和包含其的藥物組合物
HK1252643A1 (zh) 使用融合蛋白對tcr重編程的組合物和方法
IL257030A (en) Multivalent and multispecific cleavage proteins that bind to gitr Preparations containing them and uses thereof
IL250622A0 (en) Prepared sirp-alpha fusion proteins and pharmaceutical preparations containing them
HK1244019A1 (zh) 融合蛋白
HK1246315A1 (zh) 細胞因子融合蛋白
HK1247933A1 (zh) 包含bdnf的融合蛋白
IL256772B (en) DR-5 binding fusion proteins that are multivalent and multispecific and uses thereof
IL275435A (en) TATK – CDKL5 fusion proteins, preparations, formulations, and their uses
EP3419651C0 (en) IMPROVED NAGLU FUSION PROTEIN FORMULATION
HK1255586A1 (zh) 含有多肽的醫藥組合物